CB Scientific Files Application to Uplist to the OTCQB Venture Market
CB Scientific Files Application to Uplist to the OTCQB Venture Market
Upgraded listing would provide increased transparency and enhanced trading efficiency
升級後的上市將提高透明度和交易效率。
ESCONDIDO, CA / ACCESSWIRE / November 16, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") is pleased to announce that it has submitted its application to uplist to the OTCQB® Venture Market.
加利福尼亞州埃斯孔迪多/ACCESSWIRE/2021年11月16日/CB Science.Inc.(場外粉色：CBSC)CBSC(以下簡稱“CBSC”或“本公司”)很高興地宣佈，它已經提交了在OTCQB®創業板市場上市的申請。
The application itself is not a guarantee of acceptance by OTC MARKETS to go from the Company's current OTC PINK status to uplisting onto the OTCQB®. However, CB Scientific previously engaged MaloneBailey LLP to conduct a Public Company Accounting Oversight Board (PCAOB) audit and has appointed sufficient independent directors, both key requirements to be considered for uplisting.
申請本身並不保證場外市場接受該公司目前的場外粉色狀態升級到OTCQB®。然而，CB Science之前聘請了MaloneBailey LLP進行上市公司會計監督委員會(PCAOB)審計，並任命了足夠的獨立董事，這兩個關鍵要求都需要考慮才能晉升。
"If accepted, uplisting to the OTCQB® would be a critically important step for the Company as we continue to execute our business plan," said Charles Martin, Chief Executive Officer of CB Scientific. "Additionally, achieving such an auspicious milestone will certainly better position us to meet required listing standards as we work towards achieving one of our longer-term objectives of becoming a Nasdaq Capital Markets-listed company," he added.
CB Science首席執行官查爾斯·馬丁(Charles Martin)表示：“如果獲得批准，進入OTCQB®對公司來説將是至關重要的一步，因為我們將繼續執行我們的業務計劃。”“此外，在我們努力實現成為納斯達克資本市場上市公司的長期目標時，實現這樣一個吉祥的里程碑肯定會使我們更好地達到所需的上市標準。”他補充説。
The Company believes that an uplist to the OTCQB® would provide enhanced investor benefits, including more comprehensive compliance requirements, higher reporting standards, and greater access to analyst coverage.
該公司相信，OTCQB®的上行將為投資者帶來更大的好處，包括更全面的合規要求、更高的報告標準以及更多地接觸分析師覆蓋範圍。
As additional new developments occur, CB Scientific plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
隨着更多新情況的出現，世邦魏理仕計劃通過新聞稿和監管文件及時發佈公告，讓其股東、行業參與者和公開市場隨時瞭解情況。
About CB Scientific, Inc.
CB Scientific (https://cbscientificinc.com/), through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
關於CB Science，Inc.世邦魏理仕(https://cbscientificinc.com/)，)通過其國內和國際子公司，在非侵入性非侵入性心臟監護領域提供創新的產品和服務。我們的FDA和CE批准的EKG設備、基於雲的交互式採集軟件以及適用於iOS和Android平臺的智能手機應用程序為有心律異常風險的患者提供了更好的遵從性，併為醫生提供了更準確的信息。
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
公司聯繫信息：電話：(888)225-0870電子郵件：General Queries：info@cbSciences ficinc.com投資者諮詢：Robert Hesse-dorchco.bh@gmail.com關注CBSC：Twitter、Facebook、Instagram、LinkedIn、YouTube和時事通訊
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
這一信息披露可能包含“1995年私人證券訴訟法案”所涵蓋的前瞻性陳述。這些前瞻性陳述涉及推出或增強我們的服務和產品的計劃和時間，有關未來市場狀況、供需狀況的陳述，以及本新聞稿中包含的其他預期、意圖和計劃，這些都不是歷史事實，涉及風險和不確定因素。我們對未來收入的預期取決於我們開發和供應產品和服務的能力，這些產品和服務可能不是我們今天生產的，而且符合規定的規格。在本新聞稿中使用的“計劃”、“預期”、“相信”以及類似的表述通常代表前瞻性陳述。這些聲明反映了我們目前的期望。它們受到許多風險和不確定性的影響，包括但不限於技術的變化和無處不在的市場的變化。本新聞稿包括1933年“證券法”第27A節和1934年“證券法”第27E節的含義內的前瞻性陳述。本新聞稿中包含的非歷史事實的陳述可能被視為前瞻性陳述。投資者需要注意的是，前瞻性陳述本質上是不確定的。由於某些風險和不確定因素，包括但不限於獲得融資以及監管機構和股東對預期行動的批准的能力，實際業績和結果可能與本文預測或建議的大不相同。
SOURCE: CB Scientific, Inc.
資料來源：CB Science，Inc.
譯文內容由第三人軟體翻譯。